Validation of PAG1 as a new risk gene with therapeutic potential for asthma

验证 PAG1 作为具有治疗哮喘潜力的新风险基因

• 批准号: nhmrc : GNT1128493
• 负责人: A/Pr Manuel Ferreira
• 金额: $ 68.74万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/validation-pag1-new-potential-asthma/1347698
• 关键词: Validation; PAG1; new; risk; gene

About 10% of adults and children suffer from asthma in Australia. For >60% of these their asthma symptoms are not well controlled with existing treatments and so novel therapies are needed. We have recently identified PAG1 as a novel risk gene for asthma. In this study, we will conduct mouse and human studies to investigate the possibility inhibition of PAG1 might help prevent or treat asthma exacerbations.

在澳大利亚，大约 10% 的成人和儿童患有哮喘。其中超过 60% 的患者的哮喘症状无法通过现有治疗得到很好的控制，因此需要新的治疗方法。我们最近发现 PAG1 是一种新的哮喘风险基因。在这项研究中，我们将进行小鼠和人体研究，以调查抑制 PAG1 是否有助于预防或治疗哮喘恶化。